Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RM-1995 |
| Synonyms | |
| Therapy Description |
RM-1995 is an antibody-dye conjugate comprised of an anti-CD35 monoclonal antibody (Basiliximab) linked to the dye IR700, which may result in activation of the cytotoxic T-lymphocyte mediated antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RM-1995 | RM 1995|RM1995 | RM-1995 is an antibody-dye conjugate comprised of an anti-CD35 monoclonal antibody (Basiliximab) linked to the dye IR700, which may result in activation of the cytotoxic T-lymphocyte mediated antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05220748 | Phase I | Pembrolizumab + RM-1995 RM-1995 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | Withdrawn | 0 |